Rhode Island-based MindImmune Therapeutics forged a research agreement with Pfizer to develop treatments for a number of CNS disorders.
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency Versus Other Amyloid Beta-Directed Antibodies
ProMis Neurosciences Inc. reported further results of its previously announced and ongoing preclinical program for Alzheimer’s disease.
Johnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.
Pfizer Inc. is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease.
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.
Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.
Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.
Despite the failures of late-stage Alzheimer’s drugs developed by numerous companies, Biogen appears confident in the future of the company’s amyloid plaque targeting aducanumab. Biogen announced it had increased its profit potential on the drug by forking over an additional $150 million to Neurimmune Holding AG, the company from which Biogen licensed the drug. Biogen has an option to pay Neurimmune another $50 million to drop royalties by another 5 percent.
U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s via a drug development deal worth more than $200 million with unlisted biotech company Alector.